Researcher Story: Ben Stanger, MD, PhD - Pancreatic Cancer.
Ben Stanger, Ph.D., M.D. Cancer is caused by genetic changes (errors), making every cancer unique. Nevertheless, cancers share features that allow them to be grouped into categories or “subtypes.” A tumor’s subtype strongly influences its behavior, including growth rate, likelihood of responding to one therapy versus another, and probability of relapse. Knowing each tumor’s subtype.

Newswise — PHILADELPHIA — Ben Z. Stanger, MD, PhD, an associate professor of Gastroenterology in the Perelman School of Medicine at the University of Pennsylvania, has been appointed director.

Philadelphia-based Penn Medicine appointed Ben Stanger, MD, PhD, director of the Penn Pancreatic Cancer Research Center. Here's what you should know: 1. Dr. Stanger is an associate professor of gastroenterology at the university. 2. In his new position, he will lead a multidisciplinary team as it researches ways to prevent and cure pancreatic cancer. 3. Dr. Stanger was the center's scientific.

Dr. Ben Z Stanger, MD is a doctor primarily located in Philadelphia, PA. They have 23 years of experience. Their specialties include Gastroenterology and Internal Medicine. Rate Now Share your experience. Have you seen Dr. Ben Z Stanger? Write a Review Location Get Directions University Of Pennsylvania 421 Curie Blvd Ste 616 Philadelphia, PA 19104 (215) 898-1321 Specialties Dr. Ben Z Stanger.

Ben Stanger, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology at the Perelman School of Medicine, University of Pennsylvania, and Andrew Rhim, MD, a Gastroenterology Fellow in the Stanger lab, discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumour tissue is detected.

Epithelial-mesenchymal transition (EMT) is strongly implicated in tumor cell invasion and metastasis. EMT is thought to be regulated primarily at the transcriptional level through the repressive.

Ben Stanger, MD, PhD was funded for this Cancer Therapy Targets and Predictors of Therapy Response Award to study the role of BRCA2 in the development of pancreatic cancers, specifically the role of BRCA2 in metastatic disease. Dr. Stanger's team will use mice models to study the role of.